*By Chloe Aiello*
Consolidation in the health care industry won't necessarily raise drug prices, Takeda CEO Christophe Weber told Cheddar, one week after the Japanese pharmaceutical company Takeda acquired Ireland-based drugmaker Shire for north of $50 billion.
"We spend around $4 billion per year in \[research and development\] and you need a lot of financial muscle for that. That is really what's behind the scale. You are looking for scale to finance R&D. The higher your productivity, the more flexible you will be on the pricing," Weber said.
The acquisition of Shire is the largest foreign buy-out ever executed by a Japanese firm, according to [The Economist](https://www.economist.com/business/2018/12/08/takedas-acquisition-of-shire-is-japans-biggest-ever-foreign-takeover), and makes Takeda one of the world's largest drug producers. The acquisition gives Takeda greater access to the U.S. market ー it listed on the New York Stock Exchange earlier this monthー as well as to a slate of new drugs in development. Post-merger, the new company is focusing on four different disease types ー gastroenterology, oncology, neuroscience, and rare disease ー and has 21 new drugs in late-stage development.
"It's exciting for us," Weber said.
Consolidation, especially in the expensive U.S. health care system, always invites scrutiny and concern over further hikes. Even political opposites like President Trump and Sen. Elizabeth Warren (D-Mass.) have slammed drug company executives for the high cost of drugs using similar language. Trump has accused pharmaceutical companies of ["getting away with murder"](https://www.reuters.com/article/us-usa-trump-drugpricing/trump-says-pharma-getting-away-with-murder-stocks-slide-idUSKBN14V24J), while Warren said they are "raking in profits on the backs of patients."
Weber acknowledged that competition is one key to price stabilization in health care, but said rather than contribute to price hikes, his new mega-company will leverage its size to finance research.
"The issue is R&D costs a fortune, and that's why medicines are expensive ー it's because R&D is so expensive. That's really the issue. So we need to work on better productivity, better R&D productivity. We have developed a unique R&D model, I believe, in the company and that's what will give us flexibility in the future," Weber said.
Weber said he sees a future role for technology and biotech companies in health care. They can contribute to innovations ー like gene therapy, for example ー and data collection.
"We need more real-life data, how is a patient doing instead of just clinical trial data, so this is where the tech can help to generate more of this data," Weber said.
For full interview [click here](https://cheddar.com/videos/takeda-ceo-vows-responsible-pricing-after-mega-pharmaceutical-merger).
Nvidia reported a 56% increase in second-quarter revenue and a 59% rise in net income compared to a year ago.
The Rev. Al Sharpton is set to lead a protest march on Wall Street to urge corporate America to resist the Trump administration’s campaign to roll back diversity, equity and inclusion initiatives. The New York civil rights leader will join clergy, labor and community leaders Thursday in a demonstration through Manhattan’s Financial District that’s timed with the anniversary of the Civil Rights-era March on Washington in 1963. Sharpton called DEI the “civil rights fight of our generation." He and other Black leaders have called for boycotting American retailers that scaled backed policies and programs aimed at bolstering diversity and reducing discrimination in their ranks.
President Donald Trump's administration last month awarded a $1.2 billion contract to build and operate what's expected to become the nation’s largest immigration detention complex to a tiny Virginia firm with no experience running correction facilities.
Netflix CEO Ted Sarandos claims audiences don't want to watch Netflix movies in theaters, but that seems not to be the case recently.
Chipmaker Nvidia is poised to release a quarterly report that could provide a better sense of whether the stock market has been riding an overhyped artificial intelligence bubble or is being propelled by a technological boom that’s still gathering momentum.
Cracker Barrel said late Tuesday it’s returning to its old logo after critics — including President Donald Trump — protested the company’s plan to modernize.
Low-value imports are losing their duty-free status in the U.S. this week as part of President Donald Trump's agenda for making the nation less dependent on foreign goods. A widely used customs exemption for international shipments worth $800 or less is set to end starting on Friday. Trump already ended the “de minimis” rule for inexpensive items sent from China and Hong Kong, but having to pay import taxes on small parcels from everywhere else likely will be a big change for some small businesses and online shoppers. Purchases that previously entered the U.S. without needing to clear customs will be subject to the origin country’s tariff rate, which can range from 10% to 50%.
Southwest Airlines will soon require plus-size travelers to pay for an extra seat in advance if they can't fit within the armrests of one seat. This change is part of several updates the airline is making. The new rule starts on Jan. 27, the same day Southwest begins assigning seats. Currently, plus-size passengers can pay for an extra seat in advance and later get a refund, or request a free extra seat at the airport. Under the new policy, refunds are still possible but not guaranteed. Southwest said in a statement it is updating policies to prepare for assigned seating next year.
Cracker Barrel is sticking with its new logo. For now. But the chain is also apologizing to fans who were angered when the change was announced last week.
Elon Musk on Monday targeted Apple and OpenAI in an antitrust lawsuit alleging that the iPhone maker and the ChatGPT maker are teaming up to thwart competition in artificial intelligence.
